HELPING THE OTHERS REALIZE THE ADVANTAGES OF SEVITERONEL BREAST CANCER

Just like TNBC, the position of AR from the management of estrogen receptor-positive (ER+) breast cancer is a location of Lively investigation. AR is expressed in around ninety% of ER+ tumors and preclinical information implies that AR expression is affiliated with resistance to equally tamoxifen and aromatase inhibitors in ER+ mobile lines [14–1